Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 6
2017 5
2018 8
2019 12
2020 3
2021 5
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

38 results
Results by year
Filters applied: . Clear all
Page 1
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U. Lancaster LH, et al. Among authors: kirchgaessler ku. Eur Respir Rev. 2017 Dec 6;26(146):170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Eur Respir Rev. 2017. PMID: 29212837 Free PMC article. Review.
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V. Maher TM, et al. Among authors: kirchgaessler ku. Lancet Respir Med. 2020 Feb;8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. Epub 2019 Sep 29. Lancet Respir Med. 2020. PMID: 31578169 Free article. Clinical Trial.
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J, Nathan SD, Wuyts WA, Mogulkoc Bishop N, Bouros DE, Antoniou K, Guiot J, Kramer MR, Kirchgaessler KU, Bengus M, Gilberg F, Perjesi A, Harari S, Wells AU. Behr J, et al. Among authors: kirchgaessler ku. Lancet Respir Med. 2021 Jan;9(1):85-95. doi: 10.1016/S2213-2600(20)30356-8. Epub 2020 Aug 18. Lancet Respir Med. 2021. PMID: 32822614 Clinical Trial.
Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis.
Kreuter M, Lederer DJ, Cottin V, Kahn N, Ley B, Vancheri C, Weycker D, Atwood M, Kirchgaessler KU, Ryerson CJ. Kreuter M, et al. Among authors: kirchgaessler ku. Eur Respir J. 2019 Dec 12;54(6):1901188. doi: 10.1183/13993003.01188-2019. Print 2019 Dec. Eur Respir J. 2019. PMID: 31537696 Free PMC article.
The 6-min walk test as a primary end-point in interstitial lung disease.
Harari S, Wells AU, Wuyts WA, Nathan SD, Kirchgaessler KU, Bengus M, Behr J. Harari S, et al. Among authors: kirchgaessler ku. Eur Respir Rev. 2022 Aug 23;31(165):220087. doi: 10.1183/16000617.0087-2022. Print 2022 Sep 30. Eur Respir Rev. 2022. PMID: 36002171 Free article. Review.
Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study.
Wijsenbeek MS, Bendstrup E, Valenzuela C, Henry MT, Moor CC, Jouneau S, Fois AG, Moran-Mendoza O, Anees S, Mirt M, Bengus M, Gilberg F, Kirchgaessler KU, Vancheri C. Wijsenbeek MS, et al. Among authors: kirchgaessler ku. Adv Ther. 2021 Jul;38(7):4040-4056. doi: 10.1007/s12325-021-01790-y. Epub 2021 Jun 11. Adv Ther. 2021. PMID: 34117601 Free PMC article.
Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.
Maher TM, Lancaster LH, Jouneau S, Morrison L, Lederer DJ, Molina-Molina M, Bendstrup E, Kirchgaessler KU, Gilberg F, Axmann J, Petzinger U, Noble PW. Maher TM, et al. Among authors: kirchgaessler ku. Ann Am Thorac Soc. 2019 Jul;16(7):927-930. doi: 10.1513/AnnalsATS.201810-720RL. Ann Am Thorac Soc. 2019. PMID: 30950636 Free PMC article. Clinical Trial. No abstract available.
Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis.
Kreuter M, Lederer DJ, Molina-Molina M, Noth I, Valenzuela C, Frankenstein L, Weycker D, Atwood M, Kirchgaessler KU, Cottin V. Kreuter M, et al. Among authors: kirchgaessler ku. Chest. 2019 Oct;156(4):706-714. doi: 10.1016/j.chest.2019.04.015. Epub 2019 Apr 29. Chest. 2019. PMID: 31047956 Free article. Clinical Trial.
38 results